Nick Shah
Role: Associate
Sites: CDL-Toronto, CDL-Vancouver
Streams: Biomedical Engineering, Cancer
Nick Shah is a passionate and accomplished scientist with over 10 years of experience leading successful drug discovery programs. He is driven by a deep commitment to scientific innovation and a desire to make a positive impact on human health.
In his current role as Head of Quantitative Biology at Nura Bio, he works with a talented team of researchers dedicated to identifying and developing innovative therapies for neurodegenerative disease. Nura Bio has discovered NB-4746 which is currently being tested in the clinic.
Nick has a proven track record of success in driving the advancement of drug candidates from early discovery stages through preclinical development. Prior to joining Nura Bio, Nick has held leadership positions at DICE Therapeutics, RAPT Therapeutics and Flexus Biosciences and has contributed to the discovery of five drugs that are currently in advanced clinical testing for oncology and immunology indications.
Nick advises early-stage startup founders through Creative Destruction Lab. He also serves as a science fair judge for the BioGENEius Challenge and is a member of the California Life Sciences Racial and Social Equity Committee. Nick completed his PhD at the University of Toronto and a postdoctoral fellowship at Stanford University.